Evidence
Int J Mol Sci. 2024 Jan 19;25(2):1231. doi: 10.3390/ijms25021231.
ABSTRACT
Late-onset Alzheimer’s disease is the leading cause of dementia worldwide, accounting for a growing burden of morbidity and mortality. Diagnosing Alzheimer’s disease before symptoms are established is clinically challenging, but would provide therapeutic windows for disease-modifying interventions. Blood biomarkers, including genetics, proteins and metabolites, are emerging as powerful predictors of Alzheimer’s disease at various timepoints within the disease course, including at the preclinical stage. In this review, we discuss recent advances in such blood biomarkers for determining disease risk. We highlight how leveraging polygenic risk scores, based on genome-wide association studies, can help stratify individuals along their risk profile. We summarize studies analyzing protein biomarkers, as well as report on recent proteomic- and metabolomic-based prediction models. Finally, we discuss how a combination of multi-omic blood biomarkers can potentially be used in memory clinics for diagnosis and to assess the dynamic risk an individual has for developing Alzheimer’s disease dementia.
PMID:38279230 | DOI:10.3390/ijms25021231
Add to Google Keep
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D
Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️
Real-Time Evidence Search [Psychiatry]
AI Research [Andisearch.com]
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
🌐 90 Days
VR Related Evidence Matrix
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Impact of genetic predisposition to late-onset neurodegenerative diseases on early life outcomes and brain structure
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Advances in nanoprobes for molecular MRI of Alzheimer's disease
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
- Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research
- Lithium therapy's potential to lower dementia risk and the prevalence of Alzheimer's disease: a meta-analysis
- Alzheimer's Disease and Suicide: An Integrative Literature Review
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Endo-lysosomal dysfunction in neurodegenerative diseases: opinion on current progress and future direction in the use of exosomes as biomarkers
- RNA therapeutics for neurological disease
- Benefits of Music Therapy in the Cognitive Impairments of Alzheimer's-Type Dementia: A Systematic Review
- Skin-brain axis in Alzheimer's disease - Pathologic, diagnostic, and therapeutic implications: A Hypothetical Review
- Whole genome-wide sequence analysis of long-lived families (Long-Life Family Study) identifies MTUS2 gene associated with late-onset Alzheimer's disease
- Artificial intelligence and open science in discovery of disease-modifying medicines for Alzheimer's disease
- Cell type-specific functions of Alzheimer's disease endocytic risk genes
- Using Drosophila amyloid toxicity models to study Alzheimer's disease
- Biomarkers of Alzheimer's Disease Associated with Programmed Cell Death Reveal Four Repurposed Drugs
- Exploring the potential of quercetin in Alzheimer's Disease: Pharmacodynamics, Pharmacokinetics, and Nanodelivery systems
- Putative Risk Biomarkers of Bipolar Disorder in At-risk Youth
- Putative Risk Biomarkers of Bipolar Disorder in At-risk Youth
- Blood-based Biomarkers of Cerebral Small Vessel Disease
- The relationship between 11 different polygenic longevity scores, parental lifespan, and disease diagnosis in the UK Biobank
- Disentangling Sex-Dependent Effects of APOE on Diverse Trajectories of Cognitive Decline in Alzheimer's Disease
- Understanding the Complexity of Early-Onset Dementia
- Addition of inflammation-related biomarkers to the CAIDE model for risk prediction of all-cause dementia, Alzheimer's disease and vascular dementia in a prospective study
- The power of representation: Statistical analysis of diversity in US Alzheimer's disease genetics data
- Development and Assessment of a Prediction Model for Alzheimer's Disease Diagnosis Based on Thermoregulation-Related Genes
- Feasibility of Using Magnetic Resonance Spectroscopy Test Biomarkers to Diagnose Alzheimer's Disease: Systematic Evaluation and Meta-Analysis
- European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders
- Depressive Symptoms and Plasma Markers of Alzheimer's Disease and Neurodegeneration: A Coordinated Meta-Analysis of 8 Cohort Studies
- Developmental priming of early cerebrovascular ageing: Implications across a lifetime
- Branched-chain amino acids and the risks of dementia, Alzheimer's disease, and Parkinson's disease
- Genetic-based patient stratification in Alzheimer's disease
- Do microbes play a role in Alzheimer's disease?
- Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease
- Feasibility of Oral Function Evaluation According to Dementia Severity in Older Adults with Alzheimer's Disease
- Adaptive immune changes associate with clinical progression of Alzheimer's disease
- miR-519a-3p, found to regulate cellular prion protein during Alzheimer's disease pathogenesis, as a biomarker of asymptomatic stages
- Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities
- Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models
- Association of whole-person eigen-polygenic risk scores with Alzheimer's disease
- Association of whole-person eigen-polygenic risk scores with Alzheimer's disease
- Cerebrospinal fluid reference proteins increase accuracy and interpretability of biomarkers for brain diseases
- CSF biomarkers of immune activation and Alzheimer's disease for predicting cognitive impairment risk in the elderly
- NLRP3 inflammasome signalling in Alzheimer's disease
- Oculomics: A Crusade Against the Four Horsemen of Chronic Disease
- Using principal component analysis to determine which vestibular stimuli provide best biomarkers for separating Alzheimer's from mixed Alzheimer's disease
- Minimal clinically important difference in Alzheimer's disease: Rapid review
- Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study
- Sex matters in the association between cardiovascular health and incident dementia: evidence from real world data
- Hypertension: Causes and Consequences of Circadian Rhythms in Blood Pressure
- Association of Blood Metabolomics Biomarkers with Brain Metabolites and Patient-Reported Outcomes as a New Approach in Individualized Diagnosis of Schizophrenia
- Mechanisms of sex differences in Alzheimer's disease
- Recent Advances in Fluorescent Theranostics for Alzheimer's Disease: A Comprehensive Survey on Design, Synthesis, and Properties
- Molecular cross-talk between long COVID-19 and Alzheimer's disease
Evidence Blueprint
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
Multi-Omic Blood Biomarkers as Dynamic Risk Predictors in Late-Onset Alzheimer’s Disease
🌐 365 Days
VR Related Evidence Matrix
- Early Diagnosis of Alzheimer's Disease with Blood Test; Tempting but Challenging
- Present and future of Blood-Based biomarkers of Alzheimer's Disease: Beyond the classics
- Impact of genetic predisposition to late-onset neurodegenerative diseases on early life outcomes and brain structure
- Lysosomal polygenic risk is associated with the severity of neuropathology in Lewy body disease
- Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease
- Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings
- Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles
- Advances in nanoprobes for molecular MRI of Alzheimer's disease
- Blood biomarkers for Alzheimer's disease in clinical practice and trials
- Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease
- Multi-ancestry meta-analysis and fine-mapping in Alzheimer's disease
- Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals
- Application of Suggestive Biomarkers in Dementia With Lewy Bodies With Masking of Typical Clinical Symptoms by Alzheimer Disease-type Pathology
- Investigating the association between a history of depression and biomarkers of Alzheimer's disease, cerebrovascular disease, and neurodegeneration in patients with dementia
- Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease
- Alzheimer's polygenic risk scores, APOE, Alzheimer's disease risk, and dementia-related blood biomarker levels in a population-based cohort study followed over 17 years
- Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology
- Alzheimer's Disease Diagnosis in the Preclinical Stage: Normal Aging or Dementia
- Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History
- Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia
- Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk
- Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics
- Alzheimer's Disease Biomarker Detection Using Field Effect Transistor-Based Biosensor
- The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease
- Using blood transcriptome analysis for Alzheimer's disease diagnosis and patient stratification
- A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease
- Anti-amyloid antibody treatments for Alzheimer's disease
- Symptoms and age of prodromal Alzheimer's disease in Down syndrome: a systematic review and meta-analysis
- Multipredictor risk models for predicting individual risk of Alzheimer's disease
- Longitudinal changes in hippocampal texture from healthy aging to Alzheimer's disease
- CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease
- Multi-Modality, Multi-Dimensional Characterization of Pediatric Non-Alcoholic Fatty Liver Disease
- Consensus on rapid screening for prodromal Alzheimer's disease in China
- The Association of Alzheimer's Disease-Related Blood-Based Biomarkers with Cognitive Screening Test Performance in the Congolese Population in Kinshasa
- Report of the APOE4 National Institute on Aging/Alzheimer Disease Sequencing Project Consortium Working Group: Reducing APOE4 in Carriers is a Therapeutic Goal for Alzheimer's Disease
- A new diagnostic tool for brain disorders: extracellular vesicles derived from neuron, astrocyte, and oligodendrocyte
- Association between aspirin use and risk of dementia: a systematic review and meta-analysis
- New horizons in the diagnosis and management of Alzheimer's Disease in older adults
- Multiomics analysis to explore blood metabolite biomarkers in an Alzheimer's Disease Neuroimaging Initiative cohort
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review
- Association of Plasma Markers of Alzheimer's Disease, Neurodegeneration, and Neuroinflammation with the Choroid Plexus Integrity in Aging
- Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer's disease pathogenesis
- Meeting report of the fifth annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer's Disease Research
- Lithium therapy's potential to lower dementia risk and the prevalence of Alzheimer's disease: a meta-analysis
- Lower mortality risk in APOE4 carriers with normal cognitive ageing
- Alzheimer's Disease and Suicide: An Integrative Literature Review
- Gut microbiome composition may be an indicator of preclinical Alzheimer's disease
- Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics
- Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient
- Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases
- Levels of Alzheimer's disease blood biomarkers are altered after food intake-A pilot intervention study in healthy adults
- Modern Approaches to the Diagnosis of Cognitive Impairment and Alzheimer's Disease: A Narrative Literature Review
- Analytical and clinical validation of Alzheimer's disease blood biomarkers with a focus on plasma p-tau217
- The Early-Onset Alzheimer's Disease Whole-Genome Sequencing Project: Study design and methodology
- Abnormal EEG microstates in Alzheimer's disease: predictors of b-amyloid deposition degree and disease classification
- Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells
- Genetics of Alzheimer's Disease in the African American Population
- Endo-lysosomal dysfunction in neurodegenerative diseases: opinion on current progress and future direction in the use of exosomes as biomarkers
- The role of peripheral inflammatory insults in Alzheimer's disease: a review and research roadmap
- Towards a future where Alzheimer's disease pathology is stopped before the onset of dementia
- RNA therapeutics for neurological disease
- Benefits of Music Therapy in the Cognitive Impairments of Alzheimer's-Type Dementia: A Systematic Review
- CSF metabolites associated with biomarkers of Alzheimer's disease pathology